Health Canada Issues Celebrex® Warning

Return to Celebrex® homepage on SSEM.COM

Health Canada has pulled authorization of Celebrex® for the treatment of a rare genetic disease, following new information linking the drug to an increased risk of heart attack.

Two U.S. National Cancer Institute trials looking at Celebrex® as a potential treatment for cancer prevention were stopped when one showed people taking the drug were 2.5 times more likely to have a major cardiovascular event, including death.

Health Canada says Pfizer can't market Celebrex® for the treatment of Familial Adenomatous Polyposys, a disease "highly predictive" of colorectal cancer.

Celebrex® is still approved in Canada for the treatment of other conditions, such as rheumatoid arthritis and acute pain.

Pfizer says despite the warning, it would not pull the drug from the market.

If you believe that you or a relative were injured by taking Celebrex® please use the form below to contact our law firm.

Have you suffered a heart attack or stroke? (Select Yes or No)
YES
NO

Your Name:

Your E-Mail:

Your Daytime Phone Number:

Your Evening Phone Number:

Please fill in your question or comments:

References

Copyright © 1999-2008 Specter Specter Evans & Manogue, P.C.
Terms of Use | Privacy Policy